^(32)P-胶体磷酸铬联合p53基因治疗恶性胸腔积液的临床研究  

Clinical study of colloidal chromic phosphate ^(32)P combined with p53 gene for the treatment of malignant pleural effusion

作　　者：张长明[1,2] 左书耀[1] 闫瑞红[2] 

机构地区：[1]青岛大学医学院附属医院核医学科,山东青岛266021 [2]聊城市人民医院核医学科,山东聊城252000

出　　处：《泰山医学院学报》2012年第2期92-94,共3页Journal of Taishan Medical College

摘　　要：目的观察32P-胶体磷酸铬联合p53基因治疗恶性胸腔积液的近期疗效及毒副作用。方法 42例确诊为单侧恶性胸腔积液的患者,随机分为实验组和对照组。实验组用重组人p53腺病毒注射液联合32P-胶体磷酸铬治疗,对照组单用32P-胶体磷酸铬。所有治疗每月一次,治疗两次后评价疗效。结果实验组总有效率(CR+PR)为81.0%,对照组总有效率(CR+PR)为47.6%。实验组与对照组比较,差异具有统计学意义(x2=5.081,P<0.05)。结论 32P-胶体磷酸铬与p53基因联合治疗可以有效地控制恶性胸腔积液。Objective： To evaluate the recent curative effect and side effect of colloidal chromic phosphate 32p combined with p53 gene for the treatment of malignant pleural effusion. Methods ：42 patients diagnosed as single side malignant pleu- ral effusion were randomly divided into 2 groups. The patients of experimental group were treated by recombinant adenovirus p53 injection（tAD-p53） combined with colloidal chromic phosphate 32p. The patients of the control group were treated by colloidal chromic phosphate 32p per month. The therapeutic effects were evaluated after 2 courses. Results ：The total effec- tive rate （ CR ＋ PR） was 81.0% in the experimental group and 47.6% in the control group. There was significant differ- ence between the two groups （X2 = 5. 081, P 〈 0.05 ）. Conclusion：Colloidal chromic phosphate 32p and rAd - p53 is effective on malignant pleural effusion.

关 键 词：恶性胸腔积液 重组人P53腺病毒注射液 放射性核素 32P-胶体磷酸铬 

分 类 号：R730.5[医药卫生—肿瘤]